ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
NGM Bio Clinical Trial Collaboration with Merck on NGM707, an ILT2/ILT4 Dual Antagonist Antibody, in Combination KEYTRUDA®
December 07, 2021NGM Biopharmaceuticals, Inc., a biotechnology company focused on discovering and developing transformative therapeutics for patients, announced a clinical trial collaboration and supply agreement with Merck (known as MSD outside of the United States and.. -
OncoSec Releases Interim Data from Ongoing Study of TAVO, KEYTRUDA® Combo
May 23, 2019OncoSec Medical has announced interim data from KEYNOTE-890, an ongoing Phase 2 study of TAVO™ (intratumoral IL-12) in combination with KEYTRUDA® in patients with heavily pretreated ...
Pharma Sources Insight January 2025
